Related Experiment Video
Updated: Feb 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen receptor-independent prostate cancer: an emerging clinical entity
Ilyas Sahin1, Anthony E Mega1, Benedito A Carneiro1
1a Division of Hematology-Oncology, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University , Providence , RI , USA.
Abstract:
Androgen deprivation therapy remains the backbone of prostate cancer treatment given its pivotal role in the pathogenesis of prostate cancer. The growing knowledge of androgen receptor-independent (i.e. AR-null) prostate cancer cells, however, might advance the treatment paradigm of prostate cancer. Here, we examined the results of two recent studies, published in Cancer Cell by Bluemn and Shukla et al., and their impact in the future management of castration-resistant prostate cancer.
Insights
Androgen deprivation therapy is key for prostate cancer. Understanding androgen receptor-independent prostate cancer may improve future treatments for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Urology
- Cancer Research
Background:
- Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer due to its role in cancer development.
- Emerging research on androgen receptor-independent (AR-null) prostate cancer cells presents a potential shift in treatment strategies.
- Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge, necessitating novel therapeutic approaches.
Purpose of the Study:
- To analyze the implications of recent findings on AR-null prostate cancer.
- To evaluate the impact of new research on the future management of CRPC.
- To synthesize the significance of two specific studies published in Cancer Cell.
Main Methods:
- Review and analysis of two recent studies published in Cancer Cell.
- Examination of research focusing on androgen receptor-independent prostate cancer.
- Assessment of the clinical relevance for castration-resistant prostate cancer management.
Main Results:
- Recent studies highlight the existence and potential role of AR-null prostate cancer cells.
- These findings suggest that not all prostate cancer cells rely on androgen receptors for growth.
- The research provides new insights into the heterogeneity of prostate cancer, particularly in resistant forms.
Conclusions:
- Understanding AR-null prostate cancer is crucial for advancing CRPC treatment.
- The identified pathways in AR-null cells may offer new therapeutic targets.
- Future prostate cancer management strategies may need to incorporate approaches beyond traditional ADT.
Related Concept Videos
Internal Receptors
Emerging Adulthood
Introduction to Test of Independence
The test statistic for a test of independence is similar to that of a goodness-of-fit test:
Hypothesis Test for Test of Independence
H0: The two variables (factors)...
Law of Independent Assortment
Introduction Cardiac Emergencies

